Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot studyopen access
- Authors
- Lee, Min-Kyung; Lee, Jae-Hyuk; Sohn, Seo-Young; Lee, Seo Yeon; Jeong, Tae-Yoong; Kim, Sae Chul
- Issue Date
- Apr-2022
- Publisher
- BMC
- Keywords
- Tadalafil; Glycemic control; Erectile dysfunction; Type 2 diabetes
- Citation
- DIABETOLOGY & METABOLIC SYNDROME, v.14, no.1, pp.1 - 9
- Indexed
- SCIE
SCOPUS
- Journal Title
- DIABETOLOGY & METABOLIC SYNDROME
- Volume
- 14
- Number
- 1
- Start Page
- 1
- End Page
- 9
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138948
- DOI
- 10.1186/s13098-022-00825-w
- ISSN
- 1758-5996
- Abstract
- Background Phosphodiesterase type 5 inhibitors restore nitric oxide signaling, that plays a significant role in erectile function, and appears to counteract insulin resistance in animal and human models. This study was aimed to evaluate the glycemic and metabolic effects of low-dose tadalafil once daily in patients with type 2 diabetes and erectile dysfunction. Methods A 6-month, randomized, double-blind, placebo-controlled pilot trial was conducted. Eligible patients were randomly assigned in a ratio of 2:1 to the tadalafil 5 mg and placebo groups; all patients received either tadalafil or placebo once a day. The primary efficacy endpoint was the absolute change in glycated hemoglobin (HbA1c) levels during the 6-month study period. The secondary efficacy endpoints included metabolic parameters and erectile function. Results Of the 68 patients who completed this study, 45 and 23 patients were allocated to the tadalafil and placebo groups, respectively. The mean HbA1c level was significantly different between the groups over the 6-month study period (P = 0.021). After 6 months of treatment, the HbA1c decrement in the tadalafil group was greater than that in the placebo group (- 0.14 +/- 0.53% vs. 0.20 +/- 0.69%, P = 0.030). The International Index of Erectile Function-5 scores improvement was significantly greater in the tadalafil group than in the placebo group at 6 months (P = 0.003). Conclusion This prospective pilot study showed that low-dose tadalafil administered once a day was effective in improving glycemic control and erectile function in patients with type 2 diabetes and erectile dysfunction. Trial registration KCT0005666
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138948)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.